COMPANY WORKBOOK · ALNY
Alnylam Pharmaceuticals, Inc.
Healthcare & Life Sciences · Biotechnology
$244.32+1.99%
44/100
INTERACTIVE PRICE CHART
Trend and moving averages
RELATIVE PERFORMANCE
ALNY versus SPY and SMH
Indexed to 100
Cross-sectional ranking
Scores are percentile-ranked against the current Young Bull universe and stored by date in PostgreSQL.
Healthcare & Life Sciences
This company is available as a market-data workbook. Young Bull has not added a manual investment thesis for it yet.
MODEL READ
Overall score: 43.7. Last ranked 2026-09-22.
QUARTERLY FUNDAMENTALS
Revenue and earnings power
TRAILING P/E43.84
PRICE / SALES7.01
EV / EBITDA31.63
BOOK VALUEN/A
GROSS MARGIN79.7%
PROFIT MARGIN16.1%
RETURN ON EQUITY96.6%
FREE CASH FLOW271.54M
What it does
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
PRIMARY SOURCES